Study probes why women choose injections over pills to stop HIV
NCT ID NCT05799339
Summary
This study aimed to understand how women who inject drugs engage with different forms of HIV prevention medication. Researchers observed 144 women who were prescribed either a long-acting injection (CAB-LA) or daily oral pills (PrEP) to prevent HIV. The goal was to learn what influences their choice and ability to stick with the medication over six months, considering factors like housing, drug use, and past experiences with other long-acting medicines.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Prevention Point Philadelphia
Philadelphia, Pennsylvania, 19143, United States
Conditions
Explore the condition pages connected to this study.